Bamco Inc. NY Sells 88,365 Shares of West Pharmaceutical Services (WST)

Bamco Inc. NY lowered its holdings in West Pharmaceutical Services (NYSE:WST) by 4.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,708,284 shares of the medical instruments supplier’s stock after selling 88,365 shares during the quarter. Bamco Inc. NY owned approximately 2.31% of West Pharmaceutical Services worth $150,824,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Comerica Bank raised its holdings in shares of West Pharmaceutical Services by 0.9% in the 4th quarter. Comerica Bank now owns 62,742 shares of the medical instruments supplier’s stock valued at $6,293,000 after purchasing an additional 585 shares in the last quarter. Paloma Partners Management Co raised its holdings in shares of West Pharmaceutical Services by 17.5% in the 4th quarter. Paloma Partners Management Co now owns 4,424 shares of the medical instruments supplier’s stock valued at $437,000 after purchasing an additional 659 shares in the last quarter. Whittier Trust Co. of Nevada Inc. raised its holdings in shares of West Pharmaceutical Services by 53.0% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 1,994 shares of the medical instruments supplier’s stock valued at $176,000 after purchasing an additional 691 shares in the last quarter. Amalgamated Bank raised its holdings in shares of West Pharmaceutical Services by 5.5% in the 4th quarter. Amalgamated Bank now owns 15,408 shares of the medical instruments supplier’s stock valued at $1,520,000 after purchasing an additional 803 shares in the last quarter. Finally, Cambridge Trust Co. raised its holdings in shares of West Pharmaceutical Services by 7.0% in the 4th quarter. Cambridge Trust Co. now owns 12,421 shares of the medical instruments supplier’s stock valued at $1,226,000 after purchasing an additional 817 shares in the last quarter. Institutional investors and hedge funds own 92.70% of the company’s stock.

NYSE WST opened at $88.42 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.82 and a quick ratio of 2.00. The company has a market cap of $6.56 billion, a P/E ratio of 31.81, a PEG ratio of 2.89 and a beta of 1.12. West Pharmaceutical Services has a 52 week low of $89.33 and a 52 week high of $90.06.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, April 26th. The medical instruments supplier reported $0.62 EPS for the quarter, missing the consensus estimate of $0.64 by ($0.02). The firm had revenue of $415.70 million for the quarter, compared to the consensus estimate of $403.87 million. West Pharmaceutical Services had a return on equity of 14.40% and a net margin of 8.20%. The company’s revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.60 EPS. research analysts forecast that West Pharmaceutical Services will post 2.81 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 1st. Investors of record on Wednesday, July 18th will be paid a dividend of $0.14 per share. The ex-dividend date of this dividend is Tuesday, July 17th. This represents a $0.56 annualized dividend and a dividend yield of 0.63%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 20.14%.

West Pharmaceutical Services declared that its board has approved a stock repurchase program on Thursday, February 15th that permits the company to buyback 800,000 shares. This buyback authorization permits the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

Several equities research analysts have recently commented on WST shares. Zacks Investment Research upgraded shares of West Pharmaceutical Services from a “sell” rating to a “hold” rating in a report on Friday, January 26th. Goldman Sachs started coverage on shares of West Pharmaceutical Services in a report on Wednesday, January 24th. They issued a “neutral” rating and a $110.00 price target for the company. Bank of America lowered shares of West Pharmaceutical Services from a “neutral” rating to an “underperform” rating and set a $85.00 price target for the company. in a report on Wednesday, April 25th. Finally, ValuEngine lowered shares of West Pharmaceutical Services from a “hold” rating to a “sell” rating in a report on Saturday, April 7th. Four research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $106.00.

In related news, CFO William J. Federici sold 52,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 9th. The shares were sold at an average price of $87.14, for a total transaction of $4,531,280.00. Following the completion of the transaction, the chief financial officer now owns 247,019 shares in the company, valued at approximately $21,525,235.66. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.90% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply